ST. PAUL, Min.—September 12, 2019—Zepto Life Technology, an in-vitro diagnostics company with unique, accurate and multiplex-ready “lab-on-a-chip” biotechnology, earned a 1st Place finish in the RESI Boston 2019 Innovation Challenge.
About the RESI Innovation Challenge
Life Science Nation recently invited all global early-stage companies across Biotech, MedTech, Diagnostics and Digital Health to apply for the RESI Boston 2019 Innovation Challenge – a showcase designed specifically for scientist-entrepreneurs and fundraising firms beginning to accumulate compelling proof-of-concept animal data or early stage clinical data. The 30 most innovative applicants were then hand-selected by Life Science Nation’s internal scientific review board to be featured in the RESI Boston 2019 Innovation Challenge. In the competition’s final evaluation on September 11, 2019, Zepto placed first among all 30 finalists.
For more information about the RESI Innovation Challenge, please refer to the RESI conference website at http://www.resiconference.com/innovation-challenge/.
About Zepto Life Technology
Zepto Life Technology is an in-vitro diagnostics company with unique, accurate and multiplex-ready “lab-on-a-chip” biotechnology. The company is developing clinical solutions with Mayo Clinic, and improving patient outcomes through superior assay performance at patients’ exact points of need (a $12B market).
Zepto’s fully-automated Immunoassay Platform can conveniently deliver “central lab-quality” performance at almost any point of care, so we are initially working to equip emergency rooms and ambulances with highly-accurate assays for highly-sensitive Troponin (hs-TnI) – thereby accelerating myocardial injury detection. Notably, Zepto’s newest assay for hs-TnI recently achieved a detection limit of 3 ng/L (ie. 3 pg/mL).
Meanwhile, Zepto’s portable Liquid Biopsy Platform can detect 1% cancer gene mutation (eg. PIK3CA, EGFR, KRAS and BRAF) with unparalleled specificity of 99.9%+ in less than 2 hours, for accelerated cancer-related monitoring. Notably, Zepto can distinguish a SNP or any mutation with a limit of detection of 15 mutant copies per ml, regardless of the amount of non-mutant DNA. This can revolutionize the $6B tissue-based biopsy market.
This press release may contain forward-looking statements regarding future events and the future performance of Zepto Life Technology that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include, but are not limited to, statements that relate to Zepto’s business and its future, including certain company milestones, and any statements that relate to the intent, belief, plans or expectations of Zepto or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Zepto’s existing and new product candidates may not prove safe or effective, the possibility that our applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new product candidates, if approved, may not be more effective, safer or more cost efficient than competing products, our dependence on third parties for clinical trials, manufacturing, distribution and quality control, and other risks. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
ZEPTO LIFE TECHNOLOGY, LLC® is a registered trademark of Zepto Life Technology, LLC and the Zepto logos are trademarks owned by Zepto Life Technologies, LLC. .Any other trademarks are the property of their respective owners.
© 2019 Zepto Life Technology, LLC. All Rights Reserved
Jason M. Payne
Investor Relations & Business Development